FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 206 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery February 12, 2020 A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence November 19, 2020 Load more HOT NEWS Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological...
